interferons n.
Skip this Video
Download Presentation

Loading in 2 Seconds...

play fullscreen
1 / 17

Interferons - PowerPoint PPT Presentation

  • Uploaded on

Interferons. By: Katy Nassif. Discovery of Interferons. 1957 Isaacs and Lindenmann Did an experiment using chicken cell cultures Found a substance that interfered with viral replication and was therefore named interferon

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Interferons' - andrew

Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

By: Katy Nassif

discovery of interferons
Discovery of Interferons
  • 1957
  • Isaacs and Lindenmann
  • Did an experiment using chicken cell cultures
  • Found a substance that interfered with viral replication and was therefore named interferon
  • Nagano and Kojima also independently discovered this soluble antiviral protein
what are interferons
What are Interferons?
  • Naturally occurring proteins and glycoproteins
  • Secreted by eukaryotic cells in response to viral infections, tumors, and other biological inducers
  • Produce clinical benefits for disease states such as hepatitis, various cancers, multiple sclerosis, and many other diseases
  • Strucurally, they are part of the helical cytokine family which are characterized by an amino acid chain that is 145-166 amino acids long

General Action of

Interferons are small proteins released by macrophages, lymphocytes, and tissue cells infected with a virus. When a tissue cell is infected by a virus, it releases interferon. Interferon will diffuse to the surrounding cells. When it binds to receptors on the surface of those adjacent cells, they begin the production of a protein that prevents the synthesis of viral proteins. This prevents the spread of the virus throughout the body.


  • Three types of interferons: alpha, beta and gamma.
type i interferons
Type I Interferons
  • Type I: alpha and beta
  • Alpha interferons are produced by leukocytes
  • Beta interferons are produced by fibroblasts
  • Both bind to interferon cell receptors type 1 and both encoded on chromosome 9
  • They have different binding affinities but similar biological effects
  • Viral infection is the stimulus for alpha and beta expression
  • Used to mobilize our 1st line of defense against invading organisms
  • Largest group and are secreted by almost all cell types
The exact mechanism of type I interferons are not fully understood, but this is an idea of what happens:
  • Alpha and beta bind to heterodimeric receptor on cell surface.
  • Alpha receptor is made up of at least 2 polypeptide chains: IFNa-R1 and IFNa-R2
  • IFNa-R1 is involved in signal transduction
  • IFNa-R2 is the ligand-binding chain that also plays a role in signal transduction
  • Ligation induces oligomerisation and initiation of the signal transduction pathway
  • This results in phosphorylation of signal transductors and activators of transcription proteins, which translocate to the nucleous as a trimeric complex, ISGF-3.
  • ISGF-3 activates transcription of interferon stimulated genes, with many biological effects.
type ii interferon gamma
Type II Interferon (gamma)
  • Bind to type 2 receptors and its genes are encoded on chromosome 12
  • Initially believed that T helper cell type 1 lymphocytes, cytotoxic lymphocytes and natural killer cells only produced IFNg, now evidence that B cells, natural killer T cells and professional antigen-presenting
  • cells secrete IFNg also.
  • Gamma production follows activation with immune and inflammatory stimuli rather than viral infection.
  • This production is controlled by cytokines secreted by interleukin 12 and 18.
interferon gamma receptor
Interferon Gamma Receptor
  • Composed of two ligand binding IFNg-R1 chains associated with two signal transducing IFNg-R2 chains
  • The IFNg-R2 chain is generally the limiting factor in IFNg responsiveness, as the IFNg-R1 chain is usually in excess.
  • The IFNg-R1 intracellular domain contains binding spots for the Jak 1, latent cytosolic factor, signal transducer and activator of transcription (Stat1)
  • IFNg only associates with IFNg-R2 when the IFNg-R1 chain is present.

Interferon Gamma Receptor and Signalling Pathway

Receptors are encoded by separate genes (IFNGR1 and IFNGR2, respectively) that are located on different chromosomes.

As the ligand-binding (or a) chains interact with IFN-g they dimerise and become associated with two signal-transducing chains.

Receptor assembly leads to activation of the Janus kinases JAK1 and JAK2 and phosphorylation of a tyrosine residue on the intracellular domain of IFN-gR1.

This leads to the recruitment and phosphorylation of STAT1, which forms homodimers and translocates to the nucleus to activate a range of IFN-g-responsive genes.

After this, the ligand-binding chains are internalised and dissociate.

The chains are then recycled to the cell surface.

different interferon drugs
Different Interferon Drugs
  • Interferons are broken down into recombinant versions of a specific interferon subtype and purified blends of natural human interferon.
  • Many of these are in clinical use and are given intramuscularly or subcutaneously
  • Recombinant forms of alpha interferon include:
    • Alpha-2a drug name Roferon
    • Alpha-2b drug name Intron A
    • Alpha-n1 drug name Wellferon
    • Alpha-n3 drug name AlferonN
    • Alpha-con1 drug name Infergen
  • Recombinant forms of beta interferon include:
    • Beta-1a drug name Avonex
    • Beta-1b drug name Betaseron
  • Recombinant forms of gamma interferon include:
    • Gamma-1b drug name Acimmune
alpha interferon 2a roferon a
Alpha Interferon-2a (Roferon A)
  • Protein chain that is 165 amino acids long
  • Produced using recombinant DNA technology
  • Non-glycosylated protein
  • Short half life, short terminal elimination of half life, a large volume of distribution, and a larger reduction in renal clearance.
  • These problems were resolved by pegylating alpha-2a resulting in peginterferon alpha-2a that is named Pegasys.
pegylated interferon 2a pegasys
Pegylated Interferon-2a (Pegasys)

Pegasys is recombinant interferon alpha-2a that is covalently conjugated with bis-monomethoxy polyethylene glycol (PEG)


  • First developed by Davis, Abuchowski and colleagues in the 1970s
  • In early 1990s PEG attached to alpha-2a, but it lacked the required profile of improving pharmacokinetics
  • Pegylation of interferon alpha-2b was achieved with the addition of a linear PEG, designed to degrade to allow the full potency of the interferon, while achieving a longer half-life.


  • PEG moieties are inert, longchain amphiphilic molecules that are produced by linking repeating units of ethylene oxide.
  • Can be linear or branched in their structure
  • Increasing the size with PEG, the absorption and ½ life are prolongued and the clearance of the IFN is decreased.
  • Goal of pegylation is to decrease clearence, retention of biological activity, get a stable linkage and enhance water solubility


  • Pegylation is achieved by the covalent attachment of PEG derivatives that utilize amino groups of lysines and the N-terminus of polypeptide molecules as the modification site




interferon beta 2a avonex
Interferon Beta-2a (Avonex)
  • FDA approval on May 17 1996 for Relapsing Remitting MS
  • Clinical trials showed that it slowed MS progression and had an extra benefit of slowing or preventing the development of MS-related brain atropy.
  • The exact mechanism of IFN beta activity in treating MS is unknown, but studies have shown that interlukin 10 levels in the cerebrospinal fluid were increased in patients
  • Structurally IFNb-2a is a 166 amino acid glycoprotein.
  • Produced by recombinant DNA technology using genetically engineered mammalian cells which the human beta gene has been introduced into
  • Amino acid sequence is the same as human beta interferon. They are both glycosylated at the asparagines residue at position 80
  • Some side effects include:
    • Flu-like symptoms
    • Muscle aches
    • Chills
combination therapy with ribavirin
Combination Therapy with Ribavirin
  • Many times interferons and peginterferons are used in combination with Ribavirin
  • It is a purine nucleoside analogue with a modified base and a D-ribose sugar moiety
  • 1st made in 1970 by Drs. Joseph Witkowski and Roland Robins
  • It inhibits the replication of a variety of RNA and DNA viruses and is serves as an immunomodulator to enhance type 1 cytokine production. This increases the end of treatment response and reduces post-treatment relapse.
  • Mechanism is not well known, but there are 4 proposed mechanisms
  • Interferons have overlapping but different biological activities
  • Their mechanisms of action are not fully understood, therefore there is a lot of room for future growth within this field
  • Interferon based strategies can possibly be further tailored to each individual patient according to early response dynamics
  • Other immunomodulatiors that are being tested include: Zadaxin and Ceplene
  • 1. Al-Hasso, Shahla. “Interferons: An Overview.” US Pharmacist 26:06
  • 2. Alm, Gunner V. “Role of Natural Interferon-alpha Producing cells (Plasmacytoid Dendritic cells) in Autoimmunity.” Autoimmunity 36 (2003): 463-472.
  • 3. Decatris, Marios. “Potential of Interferon-alfa in Solid Tumours.” Biodrugs 16 (2002): 261-268.
  • 4. Goodsell, David S. “The Molecular Perspective: Interferons” The Oncologist 6 (2001): 374-375.
  • 5. Hertzog, Paul J. “Interferon-gamma: an overview of signals, mechanisms and functions.” Journal of Leukocyte Biology 75 (2004): 163-179.
  • 6. Lau, Johnson Y.N. “Mechanism of Action of Ribavirin in the Combination Treatment of Chronic HVC Infection.” Perspectives in Clinical Hepatology 35 (2002): 1002-1007.
  • 7. Matthews, James S. “Peginterferon Alfa-2a: A Review of Approval and Investigational Uses.” Clinical Therapeutics 26 (2004): 991-998.
  • 8. Pedder, Simon C.J. “Pegylation of Interferon Alfa: Structural and Pharmacokinetic Properties.” Seminars in Liver Disease 23 (2003): 19-21.
  • 9. Schreiber, Gregory H. “Interferon gamma.” The Cytokine Handbook 4 (2003):567-569.
  • 10. Vrolijk, J.M. “The treatment of hepatitis C: history, presence and future.” Journal of Medicine 62 (2004): 76-82.